Fabian Meili
Fabian Meili has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Christopher Leonard Brett
Concordia University
13 shared publications - Jesse T. Chao
Department of Medical Biophysics, Sunnybrook Research Institute, The University of Toronto, 2075 Bayview Avenue, E240, Toronto, Ontario, Canada, M4N 3M5
13 shared publications - Warren M. Meyers
Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada
13 shared publications Kurt Haas
12 shared publicationsCalvin D. Roskelley
11 shared publications- Douglas M. Fowler
Department of Genome Sciences, University of Washington, Seattle, WA, USA
11 shared publications
Latest Publications
- Open Access
- 19 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-5
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
- 19 August 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-5
Open AccessAuthor Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
- Open Access
- 4 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug discovery. So far only a few ligases have been utilized for TPD. Interestingly, the workhorse ligase CRBN has been observed to be downregulated in settings of resistance to immunomodulatory inhibitory drugs (IMiDs). Here we show that the essential E3 ligase receptor DCAF1 can be harnessed for TPD utilizing a selective, non-covalent DCAF1 binder. We confirm that this binder can be functionalized into an efficient DCAF1-BRD9 PROTAC. Chemical and genetic rescue experiments validate specific degradation via the CRL4DCAF1 E3 ligase. Additionally, a dasatinib-based DCAF1 PROTAC successfully degrades cytosolic and membrane-bound tyrosine kinases. A potent and selective DCAF1-BTK-PROTAC (DBt-10) degrades BTK in cells with acquired resistance to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an alternative strategy to tackle intrinsic resistance to VHL-degrader, highlighting DCAF1-PROTACS as a promising strategy to overcome ligase mediated resistance in clinical settings.
- 4 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessDCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
Targeted protein degradation (TPD) mediates protein level through small molecule induced redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal degradation. TPD has recently emerged as a key modality in drug discovery. So far only a few ligases have been utilized for TPD. Interestingly, the workhorse ligase CRBN has been observed to be downregulated in settings of resistance to immunomodulatory inhibitory drugs (IMiDs). Here we show that the essential E3 ligase receptor DCAF1 can be harnessed for TPD utilizing a selective, non-covalent DCAF1 binder. We confirm that this binder can be functionalized into an efficient DCAF1-BRD9 PROTAC. Chemical and genetic rescue experiments validate specific degradation via the CRL4DCAF1 E3 ligase. Additionally, a dasatinib-based DCAF1 PROTAC successfully degrades cytosolic and membrane-bound tyrosine kinases. A potent and selective DCAF1-BTK-PROTAC (DBt-10) degrades BTK in cells with acquired resistance to CRBN-BTK-PROTACs while the DCAF1-BRD9 PROTAC (DBr-1) provides an alternative strategy to tackle intrinsic resistance to VHL-degrader, highlighting DCAF1-PROTACS as a promising strategy to overcome ligase mediated resistance in clinical settings.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
As sequencing becomes more economical, we are identifying sequence variations in the population faster than ever. For disease-associated genes, it is imperative that we differentiate a sequence variant as either benign or pathogenic, such that the appropriate therapeutic interventions or surveillance can be implemented. PTEN is a frequently mutated tumor suppressor that has been linked to the PTEN hamartoma tumor syndrome. Although the domain structure of PTEN and the functional impact of a number of its most common tumor-linked mutations have been characterized, there is a lack of information about many recently identified clinical variants. To address this challenge, we developed a cell-based assay that utilizes a premalignant phenotype of normal mammary epithelial cells lacking PTEN. We measured the ability of PTEN variants to rescue the spheroid formation phenotype of PTEN−/− MCF10A cells maintained in suspension. As proof of concept, we functionalized 47 missense variants using this assay, only 19 of which have clear classifications in ClinVar. We utilized a machine learning model trained with annotated genotypic data to classify variants as benign or pathogenic based on our functional scores. Our model predicted with high accuracy that loss of PTEN function was indicative of pathogenicity. We also determined that the pathogenicity of certain variants may have arisen from reduced stability of the protein product. Overall, this assay outperformed computational predictions, was scalable, and had a short run time, serving as an ideal alternative for annotating the clinical significance of cancer-associated PTEN variants.Significance:Combined three-dimensional tumor spheroid modeling and machine learning classifies PTEN missense variants, over 70% of which are currently listed as variants of uncertain significance.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
As sequencing becomes more economical, we are identifying sequence variations in the population faster than ever. For disease-associated genes, it is imperative that we differentiate a sequence variant as either benign or pathogenic, such that the appropriate therapeutic interventions or surveillance can be implemented. PTEN is a frequently mutated tumor suppressor that has been linked to the PTEN hamartoma tumor syndrome. Although the domain structure of PTEN and the functional impact of a number of its most common tumor-linked mutations have been characterized, there is a lack of information about many recently identified clinical variants. To address this challenge, we developed a cell-based assay that utilizes a premalignant phenotype of normal mammary epithelial cells lacking PTEN. We measured the ability of PTEN variants to rescue the spheroid formation phenotype of PTEN−/− MCF10A cells maintained in suspension. As proof of concept, we functionalized 47 missense variants using this assay, only 19 of which have clear classifications in ClinVar. We utilized a machine learning model trained with annotated genotypic data to classify variants as benign or pathogenic based on our functional scores. Our model predicted with high accuracy that loss of PTEN function was indicative of pathogenicity. We also determined that the pathogenicity of certain variants may have arisen from reduced stability of the protein product. Overall, this assay outperformed computational predictions, was scalable, and had a short run time, serving as an ideal alternative for annotating the clinical significance of cancer-associated PTEN variants.Significance:Combined three-dimensional tumor spheroid modeling and machine learning classifies PTEN missense variants, over 70% of which are currently listed as variants of uncertain significance.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Data from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
As sequencing becomes more economical, we are identifying sequence variations in the population faster than ever. For disease-associated genes, it is imperative that we differentiate a sequence variant as either benign or pathogenic, such that the appropriate therapeutic interventions or surveillance can be implemented. PTEN is a frequently mutated tumor suppressor that has been linked to the PTEN hamartoma tumor syndrome. Although the domain structure of PTEN and the functional impact of a number of its most common tumor-linked mutations have been characterized, there is a lack of information about many recently identified clinical variants. To address this challenge, we developed a cell-based assay that utilizes a premalignant phenotype of normal mammary epithelial cells lacking PTEN. We measured the ability of PTEN variants to rescue the spheroid formation phenotype of PTEN−/− MCF10A cells maintained in suspension. As proof of concept, we functionalized 47 missense variants using this assay, only 19 of which have clear classifications in ClinVar. We utilized a machine learning model trained with annotated genotypic data to classify variants as benign or pathogenic based on our functional scores. Our model predicted with high accuracy that loss of PTEN function was indicative of pathogenicity. We also determined that the pathogenicity of certain variants may have arisen from reduced stability of the protein product. Overall, this assay outperformed computational predictions, was scalable, and had a short run time, serving as an ideal alternative for annotating the clinical significance of cancer-associated PTEN variants.Significance:Combined three-dimensional tumor spheroid modeling and machine learning classifies PTEN missense variants, over 70% of which are currently listed as variants of uncertain significance.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
As sequencing becomes more economical, we are identifying sequence variations in the population faster than ever. For disease-associated genes, it is imperative that we differentiate a sequence variant as either benign or pathogenic, such that the appropriate therapeutic interventions or surveillance can be implemented. PTEN is a frequently mutated tumor suppressor that has been linked to the PTEN hamartoma tumor syndrome. Although the domain structure of PTEN and the functional impact of a number of its most common tumor-linked mutations have been characterized, there is a lack of information about many recently identified clinical variants. To address this challenge, we developed a cell-based assay that utilizes a premalignant phenotype of normal mammary epithelial cells lacking PTEN. We measured the ability of PTEN variants to rescue the spheroid formation phenotype of PTEN−/− MCF10A cells maintained in suspension. As proof of concept, we functionalized 47 missense variants using this assay, only 19 of which have clear classifications in ClinVar. We utilized a machine learning model trained with annotated genotypic data to classify variants as benign or pathogenic based on our functional scores. Our model predicted with high accuracy that loss of PTEN function was indicative of pathogenicity. We also determined that the pathogenicity of certain variants may have arisen from reduced stability of the protein product. Overall, this assay outperformed computational predictions, was scalable, and had a short run time, serving as an ideal alternative for annotating the clinical significance of cancer-associated PTEN variants.Significance:Combined three-dimensional tumor spheroid modeling and machine learning classifies PTEN missense variants, over 70% of which are currently listed as variants of uncertain significance.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S3 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Premalignant Cell-Based Model for Functionalization and Classification of PTEN Variants